H.C. Wainwright Initiates a Hold Rating on SAGE Therapeutics (SAGE)

By Carrie Williams

SAGE Therapeutics (SAGEResearch Report) received a Hold rating and a $160.00 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed last Monday at $140.16.

According to TipRanks.com, Tsao is a 1-star analyst with an average return of -1.4% and a 45.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Outlook Therapeutics Inc, and Protagonist Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $207.13 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $193.56 and a one-year low of $79.88. Currently, SAGE Therapeutics has an average volume of 373.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.